• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Daiichi Sankyo Company (TSE:4568) Could Be 36% Below Fair Value As Enhertu Wins EU Approval

    Simply Wall St·10/30/2026 04:48:24
    Listen to the news

    Daiichi Sankyo Company (TSE:4568) just cleared a major regulatory hurdle in Europe. The European Commission approved Enhertu as an adjuvant monotherapy for certain HER2 positive breast cancer patients with residual invasive disease.

    Daiichi Sankyo Company’s latest EU green light for Enhertu lands after a choppy stretch for holders, with the 1-day share price return of 1.45% offering a brief lift against a year-to-date share price decline of 25.85% and a 1-year total shareholder return down 29.71%, so recent oncology milestones sit against longer term performance that has yet to recover.

    Spot under-pressure oncology plays like Daiichi Sankyo Company and compare them with handpicked 10 healthcare AI stocks, which are gaining attention off the back of fresh cancer and AI driven treatment breakthroughs.

    After a 1.45% bounce leaves Daiichi Sankyo shares still trading well below earlier levels, analyst targets and intrinsic value estimates sit far higher. Is that gap justified by the risks, or does it overstate them?

    Most Popular Narrative: 36% Undervalued

    Daiichi Sankyo Company’s widely followed thesis points to a fair value of ¥4,077.5, well above the last close at ¥2,617.5, so the current quotation reflects a steep narrative gap that depends on oncology execution and capital allocation actually playing out as outlined.

    Planned expansion of the DXd antibody drug conjugate franchise, with five DXd products already launched or in late stage development and more than 20 new indications and over 20 pivotal readouts expected over the next five years, creates multiple opportunities for additional oncology revenue streams and potential margin support as the portfolio scales.

    See why 8 investors see Daiichi Sankyo Company as 36% undervalued.

    Result: Fair Value of ¥4,077.5 (UNDERVALUED)

    Still, the bullish Daiichi Sankyo Company story can crack if Enhertu or Datroway underdeliver, or if hefty ADC related costs drag on profitability longer than expected.

    Find out about the key risks to this Daiichi Sankyo Company narrative.

    Next Steps

    Mixed signals around Daiichi Sankyo can make the story feel messy, so move fast, pull up the underlying metrics, and pressure test the bullish and bearish angles for yourself using the 2 key rewards and 3 important warning signs.

    Looking for more investment ideas beyond Daiichi Sankyo Company?

    If you stop with just Daiichi Sankyo Company, you only see one angle. Widen your watchlist and pressure test your thesis against other compelling setups.